Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Executive Summary
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
You may also be interested in...
Testimonials Lead To Overbroad Claims, DDMAC Warning Letter Says
Implied efficacy claims from a physician and patients for Testopel testosterone pellets, among many other problems with a series of promotional pieces, draw a warning letter to Slate Pharmaceuticals.
Testimonials Lead To Overbroad Claims, DDMAC Warning Letter Says
Implied efficacy claims from a physician and patients for Testopel testosterone pellets, among many other problems with a series of promotional pieces, draw a warning letter to Slate Pharmaceuticals.
Testosterone Gel Makers Brace For REMS, Black Box Warning
Risks of skin contact with children and women were known, but severity of adverse events took the field by surprise.